JointHealth™ express June 9, 2008
Great news for people in Quebec living with moderate to severe rheumatoid arthritis: rituximab (Rituxan®) has been added to the provincial medication reimbursement plan. Rituximab will be available to people with moderate to severe rheumatoid arthritis on a case-by-case basis.
With this listing, Quebec becomes the first province in the country to provide reimbursement coverage for every medication approved to treat the three most common types of inflammatory arthritis: rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Arthritis Consumer experts congratulates Quebec for offering physicians and patients the tools they need to treat inflammatory forms of arthritis.
Great news for people in Quebec living with moderate to severe rheumatoid arthritis: rituximab (Rituxan®) has been added to the provincial medication reimbursement plan. Rituximab will be available to people with moderate to severe rheumatoid arthritis on a case-by-case basis.
With this listing, Quebec becomes the first province in the country to provide reimbursement coverage for every medication approved to treat the three most common types of inflammatory arthritis: rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Arthritis Consumer experts congratulates Quebec for offering physicians and patients the tools they need to treat inflammatory forms of arthritis.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.